Loading company…
ID 212153667 · FY 2018–2024 · 7 years
კომპანიის ძირითად საქმიანობას წარმოადგენს ფარმაცევტული პრეპარატების წარმოება.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 7,068 | 6,619 | 10,847 | 12,858 | 12,412 | 9,686 | 10,150 | +6.2% |
| Total COGS | -5,301 | -1 | -7,675 | -7,942 | -6,317 | -4,651 | -4,625 | -2.2% |
| Gross Profit | 1,767 | 6,618 | 3,173 | 4,915 | 6,095 | 5,035 | 5,525 | +20.9% |
| Gross Margin | 25.0% | 100.0% | 29.3% | 38.2% | 49.1% | 52.0% | 54.4% | |
| Total Operating Expenses | -1,590 | -7,146 | -2,940 | -3,892 | -5,707 | -5,462 | -6,373 | +26.0% |
| EBITDA | 178 | -528 | 233 | 1,023 | 388 | -427 | -847 | nmf |
| EBITDA Margin | 2.5% | -8.0% | 2.1% | 8.0% | 3.1% | -4.4% | -8.3% | |
| Total D&A | -520 | -549 | -281 | -292 | -362 | -491 | -313 | -8.1% |
| EBIT / Operating Income | -343 | -1,077 | -48 | 731 | 26 | -918 | -1,161 | +22.5% |
| Total Other Income | -137 | -419 | 112 | -46 | -186 | -192 | -115 | -2.9% |
| Profit Before Tax | -480 | -1,496 | 64 | 684 | -160 | -1,110 | -1,276 | +17.7% |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | -732 | -947 | 214 | 938 | -160 | -1,110 | -1,276 | +9.7% |
| Net Margin | -10.4% | -14.3% | 2.0% | 7.3% | -1.3% | -11.5% | -12.6% | |
| Other Comprehensive Income | 0 | 0 | 2,385 | 2,385 | 2,385 | 2,385 | 2,385 | +0.0% |
| Total Comprehensive Income | -732 | -947 | 2,599 | 3,323 | 2,225 | 1,275 | 1,109 | nmf |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).